ABUS RNAi Play
06.08.15 11:35
#277
klandestino
habe CC angefragt
ich poste die Antwort, falls nicht vorher jmd etwas weiss..
06.08.15 13:14
#278
JaRy
Tekmira
Tekmira hat sich in Arbutus umbenannt. Dauert anscheindend noch bis der Namenswechsel auch bei den Aktiendepots abgeschlossen ist.
06.08.15 13:16
#279
JaRy
Korrektur
Ok, gibt's eh schon:
http://www.aktiencheck.de/arbutus_biopharma-aktie/
http://www.aktiencheck.de/arbutus_biopharma-aktie/
06.08.15 19:20
#280
klandestino
Die Antwort von CC
Laut den uns vorliegenden Informationen fand per 31.07.2015 in der Gattung WKN A1C8KJ ein obligatorischer Umtausch im Verhältnis 1:1 in die Gattung WKN A14XKC statt. Sobald wir die neuen Stücke von der Lagerstelle erhalten, buchen wir sie in die Kundendepots ein. Bei Wertpapieren, die im Ausland gelagert sind, kann es einen längeren Zeitraum dauern, als Sie es eventuell von inländischen Papieren gewöhnt sind. Bitte haben Sie noch etwas Geduld. Die entsprechenden Umbuchungsbelege finden Sie dann im OnlineArchiv.
07.08.15 19:47
#282
braunjosef
Arbutus
bei mir wurden sie schon gestern unter
dem neuen namen eingebucht.
im moment habe ich ca. 40% minus, meint ihr dass sie wieder kommen?
14.08.15 21:54
#283
TengriLethos
ob sie wieder kommen ?
Das wollen wir doch hoffen !
Arbutus ist nicht einfach eine kleine Biotech-Bude.
Das Arsenal an Hep B Produktekandidaten ist beachtlich, und insbesondere TKM-HBV hat Blockbuster-Potential.
Leider ist alles noch in frühen Phasen, und der Titel entsprechend volatil und möglicherweise ein Langsamläufer.
Die Hochs bei 20-30 Kanada Dollar waren ebola-hype-bedingt. Im Moment ist das Interesse sehr klein.
Geduld dürfte hier Rosen bringen.
Arbutus ist nicht einfach eine kleine Biotech-Bude.
Das Arsenal an Hep B Produktekandidaten ist beachtlich, und insbesondere TKM-HBV hat Blockbuster-Potential.
Leider ist alles noch in frühen Phasen, und der Titel entsprechend volatil und möglicherweise ein Langsamläufer.
Die Hochs bei 20-30 Kanada Dollar waren ebola-hype-bedingt. Im Moment ist das Interesse sehr klein.
Geduld dürfte hier Rosen bringen.
15.10.15 22:18
#284
hhsjgmr
gute nachrichten ??
15. Oktober 2015
Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer, Named Economist 2015 Innovation Award Gewinner in der Kategorie Biowissenschaften
Vancouver, British Columbia und Doylestown, Pa, 15. Oktober 2015 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation. (Nasdaq: ABUS), konzentrierte sich eine Industrie-führende therapeutische Lösungen Unternehmen auf die Entwicklung einer Heilung für chronische Hepatitis B-Virusinfektion (HBV ), gab heute bekannt, dass Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer hat der Economist 2015 Innovation Award in der Kategorie Bioscience gewonnen, für die Entwicklung einer schnellen Heilung für Hepatitis-C-Virus-Infektion (HCV).
HCV betrifft 150 Millionen Menschen weltweit mit einer jährlichen Sterblichkeitsrate von einer halben Million Patienten weltweit. Während herkömmliche Behandlungen etwa 50 Prozent der Fälle nach so viel wie ein Jahr der Therapie nur zu heilen, Sovaldi (ursprünglich genannt Sofosbuvir nach seinem Erfinder, Dr. Sofia) können 90 Prozent der Patienten in nur 12 bis 24 Wochen zu heilen.
"Ich fühle mich geehrt, ausgewählt worden zu sein, um den 2015 Innovation Award in Biosciences erhalten. Es ist eine Anerkennung der echte Hoffnung, dass Sofosbuvir gibt nun für die Leiden von den schwächenden Auswirkungen von HCV und der Realität, dass sie freuen uns jetzt auf einem normalen Leben frei von dieser Krankheit ", sagte Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer. "Bei Arbutus unser Fokus auf der Entwicklung einer kurativen Therapie für Patienten mit HBV, eine Krankheit mit einer noch höheren Prävalenz und größeren medizinischen Bedarf. Wir setzen Erfahrungen aus HCV, unsere Strategie für den Aufbau der führenden HBV-Pipeline und die Entwicklung eigener Medikamente zu informieren Kombinatio
Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer, Named Economist 2015 Innovation Award Gewinner in der Kategorie Biowissenschaften
Vancouver, British Columbia und Doylestown, Pa, 15. Oktober 2015 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation. (Nasdaq: ABUS), konzentrierte sich eine Industrie-führende therapeutische Lösungen Unternehmen auf die Entwicklung einer Heilung für chronische Hepatitis B-Virusinfektion (HBV ), gab heute bekannt, dass Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer hat der Economist 2015 Innovation Award in der Kategorie Bioscience gewonnen, für die Entwicklung einer schnellen Heilung für Hepatitis-C-Virus-Infektion (HCV).
HCV betrifft 150 Millionen Menschen weltweit mit einer jährlichen Sterblichkeitsrate von einer halben Million Patienten weltweit. Während herkömmliche Behandlungen etwa 50 Prozent der Fälle nach so viel wie ein Jahr der Therapie nur zu heilen, Sovaldi (ursprünglich genannt Sofosbuvir nach seinem Erfinder, Dr. Sofia) können 90 Prozent der Patienten in nur 12 bis 24 Wochen zu heilen.
"Ich fühle mich geehrt, ausgewählt worden zu sein, um den 2015 Innovation Award in Biosciences erhalten. Es ist eine Anerkennung der echte Hoffnung, dass Sofosbuvir gibt nun für die Leiden von den schwächenden Auswirkungen von HCV und der Realität, dass sie freuen uns jetzt auf einem normalen Leben frei von dieser Krankheit ", sagte Dr. Michael J. Sofia, Arbutus 'Chief Scientific Officer. "Bei Arbutus unser Fokus auf der Entwicklung einer kurativen Therapie für Patienten mit HBV, eine Krankheit mit einer noch höheren Prävalenz und größeren medizinischen Bedarf. Wir setzen Erfahrungen aus HCV, unsere Strategie für den Aufbau der führenden HBV-Pipeline und die Entwicklung eigener Medikamente zu informieren Kombinatio
20.07.16 09:56
#287
ricardo_rs
Arbutus ... 100% ... ab heute erst recht :-)
... braucht aber noch viel Geduld und bei Pharmas auch Glück -
glaube aber grundsätzlich an die Nobelpreisträger und
bin auch im Boot.
Gruss rs
glaube aber grundsätzlich an die Nobelpreisträger und
bin auch im Boot.
Gruss rs
17.11.16 10:51
#288
Mr.H
Arbutus Presents HBV Drug Combination Studies at A
November 14, 2016
Arbutus Presents HBV Drug Combination Studies at AASLD
Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action
Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis
Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program
VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in two oral presentations and one poster presentation at the 2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held on November 11-15, 2016, in Boston. These presentations feature two Arbutus pipeline programs and highlight the potential of Arbutus' combination development strategy with robust preclinical data showing complementary action when combining Arbutus assets with approved HBV therapies.
"We are very excited to present, for the first time, results from the triple combination of HBV targeting drugs in preclinical models. These in vivo study results demonstrate the promise of our proprietary compounds individually and, more importantly, in combination," said Dr. Michael Sofia, Arbutus' Chief Scientific Officer. "Our strategy is based on the concept that combining multiple drugs with complementary mechanisms of action will provide the best chance to produce HBV cures. Our in vivo preclinical study results preview the complementary action that we expect to demonstrate clinically when we combine multiple Arbutus product candidates with approved HBV therapies."
Oral Presentation #233: "The HBV Capsid inhibitor AB-423 Exhibits a Dual Mode of Action and Displays Additive/Synergistic Effects in In Vitro Combination Studies"
AB-423 is a pan-genotypic, HBV selective agent with a dual mechanism of action. It inhibits pgRNA encapsidation resulting in potent and highly selective inhibition of HBV replication. AB-423 also inhibits cccDNA formation via inhibition of the capsid uncoating step. Combination of AB-423 with ARB-1467 results in additive or synergistic activity compared to each agent alone.
Poster # 1865: "Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection"
ARB-1740 (a pan-genotypic second-generation siRNA therapeutic) suppresses multiple elements of HBV including: HBsAg, HBeAg, DNA, core antigen, and all RNAs including the HBx transcript, as demonstrated in vivo. ARB-1740 also shows significant potency advantages compared to ARB-1467 as well as an extended duration of action. ARB-1740 complements standard-of-care NUC and inhibits NUC-resistant virus variants.
Oral Presentation #232: "Exploring Combination Therapy for Curing HBV: Preclinical Studies with Capsid Inhibitor AB-423 and a siRNA Agent, ARB-1740"
In preclinical studies, a combination of AB-423 with ARB-1740 shows synergistic activity against HBV rcDNA in vitro, as well as inhibition of HBV DNA and serum HBsAg in in vivo models. Triple combinations consisting of AB-423+ARB-1740 with ETV or PegIFN provide the greatest reduction in serum HBV DNA. ARB-1740 further increases host response when added to AB-423+PegIFN, and supports the hypothesis that HBV antigen removal promotes immune recognition and viral clearance.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about two oral presentations and one poster presentation at the 2016 Annual Meeting of the American Association for the Study of Liver Diseases; clinically demonstrating complementary action when combining Arbutus assets with approved HBV therapies; the ability of HBV antigen removal to promote immune recognition and viral clearance; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus' assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com
Helia Baradarani
Senior Manager, Investor Relations
Phone: 604-419-3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
Arbutus Presents HBV Drug Combination Studies at AASLD
Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action
Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis
Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program
VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today presented results from preclinical studies of HBV drugs in two oral presentations and one poster presentation at the 2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held on November 11-15, 2016, in Boston. These presentations feature two Arbutus pipeline programs and highlight the potential of Arbutus' combination development strategy with robust preclinical data showing complementary action when combining Arbutus assets with approved HBV therapies.
"We are very excited to present, for the first time, results from the triple combination of HBV targeting drugs in preclinical models. These in vivo study results demonstrate the promise of our proprietary compounds individually and, more importantly, in combination," said Dr. Michael Sofia, Arbutus' Chief Scientific Officer. "Our strategy is based on the concept that combining multiple drugs with complementary mechanisms of action will provide the best chance to produce HBV cures. Our in vivo preclinical study results preview the complementary action that we expect to demonstrate clinically when we combine multiple Arbutus product candidates with approved HBV therapies."
Oral Presentation #233: "The HBV Capsid inhibitor AB-423 Exhibits a Dual Mode of Action and Displays Additive/Synergistic Effects in In Vitro Combination Studies"
AB-423 is a pan-genotypic, HBV selective agent with a dual mechanism of action. It inhibits pgRNA encapsidation resulting in potent and highly selective inhibition of HBV replication. AB-423 also inhibits cccDNA formation via inhibition of the capsid uncoating step. Combination of AB-423 with ARB-1467 results in additive or synergistic activity compared to each agent alone.
Poster # 1865: "Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection"
ARB-1740 (a pan-genotypic second-generation siRNA therapeutic) suppresses multiple elements of HBV including: HBsAg, HBeAg, DNA, core antigen, and all RNAs including the HBx transcript, as demonstrated in vivo. ARB-1740 also shows significant potency advantages compared to ARB-1467 as well as an extended duration of action. ARB-1740 complements standard-of-care NUC and inhibits NUC-resistant virus variants.
Oral Presentation #232: "Exploring Combination Therapy for Curing HBV: Preclinical Studies with Capsid Inhibitor AB-423 and a siRNA Agent, ARB-1740"
In preclinical studies, a combination of AB-423 with ARB-1740 shows synergistic activity against HBV rcDNA in vitro, as well as inhibition of HBV DNA and serum HBsAg in in vivo models. Triple combinations consisting of AB-423+ARB-1740 with ETV or PegIFN provide the greatest reduction in serum HBV DNA. ARB-1740 further increases host response when added to AB-423+PegIFN, and supports the hypothesis that HBV antigen removal promotes immune recognition and viral clearance.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about two oral presentations and one poster presentation at the 2016 Annual Meeting of the American Association for the Study of Liver Diseases; clinically demonstrating complementary action when combining Arbutus assets with approved HBV therapies; the ability of HBV antigen removal to promote immune recognition and viral clearance; and discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the continued demand for Arbutus' assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com
Helia Baradarani
Senior Manager, Investor Relations
Phone: 604-419-3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
23.11.16 18:21
#289
Thomy
A14XMD wo/wann geht die Reise los ?
Hallo,
ich bin hier ziemlich neu und würde von euch eine Meinung zu dieser Aktie wissen ?
Was ist hier dran ?
Wo geht die Reise hier noch bis Ende des Jahres, oder 2017 hin ? weiter Richtung 0 ?
Vielen Dank
Thomy
PS: kennt jemand die Firma genauer ? d.h. vor Ort zufällig mal gewesen ?
ich bin hier ziemlich neu und würde von euch eine Meinung zu dieser Aktie wissen ?
Was ist hier dran ?
Wo geht die Reise hier noch bis Ende des Jahres, oder 2017 hin ? weiter Richtung 0 ?
Vielen Dank
Thomy
PS: kennt jemand die Firma genauer ? d.h. vor Ort zufällig mal gewesen ?
22.06.17 18:20
#293
Mr.H
Arbutus bewegt sich....
Wird auch mal wieder zeit das es Richtung Norden geht..... Zukunft sieht vielversprechend.
Übernahme nicht ausgeschlossen.
Übernahme nicht ausgeschlossen.
21.09.17 00:26
#297
centsucher
Upcoming Company Milestones
Sept. 2017* Patisiran (Alnylam)
Phase III results (ABUS to receive royalties on sales)
*Timing per public Alnylam comments Enable filing/approval 
Sept. 2017 ARB-1467 (RNAi) Topline Phase II Cohort 4
(bi-weekly multi-dosing) study results
Faster/greater HBsAg reduction, extended dosing
Oct. 2017 AASLD Conference
6 Abstracts accepted for presentation Top-line data from clinical/preclinical programs
4Q17 AB-423 (Capsid Inhibitor) Initiate MAD study in HBV patients
Safety/PK, initial efficacy evaluation
4Q17 ARB-1467
Initiate longer duration studies with nuc and IFN Maximize HBsAg reduction
Cash as of 6/30/17: $115.6 million
Cash runway into late 2018
Opportunity to significantly extend runway with non-dilutive funding
Shares outstanding: 55.0 million basic, 60.6 million fully diluted
http://investor.arbutusbio.com/static-files/...4a7f-8476-eb3cd25a1606
25.09.17 06:37
#299
mb048
Hände weg von Pharmatiteln
auch dieser Pharma bzw. Medizin Wert wird in Kürze vom Kurszettel verschwinden.
Bloß nicht einsteigen, egal wie verlockend die Kurserwartungen mancher Schreiber auch sein mögen.
Better to wait one week and buy Bed, Bath and Beyond.
Zum Nasdaq: Crash voraus ab Montag Nachmittag (Kursziel 4.000)
Apple, Alphabet und Tesla strong sell
Amazon und Facebook sell until Friday, maybe buy in October
Bloß nicht einsteigen, egal wie verlockend die Kurserwartungen mancher Schreiber auch sein mögen.
Better to wait one week and buy Bed, Bath and Beyond.
Zum Nasdaq: Crash voraus ab Montag Nachmittag (Kursziel 4.000)
Apple, Alphabet und Tesla strong sell
Amazon und Facebook sell until Friday, maybe buy in October
25.09.17 15:05
#300
Stefan1607
Begründung zur Kursveraussage 32$
http://www.globenewswire.com/news-release/2017/09/...II-Cohort-4.html